Selective serotonin reuptake inhibitors in mixed anxiety - depression

International Clinical Psychopharmacology

Volumn 15, Issue SUPPL. 2, 2000, Pages

  Berk, M ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

Anxiety; Depression; Panic disorder; Post traumatic stress disorder; Social anxiety disorder; SSRIs

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ANXIETY NEUROSIS; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; HUMAN; NEUROTRANSMISSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SOCIAL PHOBIA;

EID: 0033753668     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200008002-00007     Document Type: Conference Paper

References (56)

1. Effects of fluvoxamine on the treatment of panic disorder: A placebo-controlled trial
2. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia
3. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
4. Sertraline in the treatment of depressive disorders associated with anxiety
5. Fluoxetine for childhood anxiety disorders
6. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder
7. The diagnostic validity of anxiety disorders and their relation to depressive illness
8. Double-blind pilot trial of desipramine versus fluoxetine in panic patients
9. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder
10. Pharmacotherapy of social anxiety disorder
11. Fluvoxamine in civilians with posttraumatic stress disorder
12. Serotonin function in panic disorder: A double-blind placebo-controlled study with fluvoxamine and ritanserin
13. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients
14. Systematic review of the outcome of anxiety and depressive disorders
15. An open trial of fluoxetine in the treatment of panic attacks
16. The neurobiological basis of mixed depression-anxiety states
17. Effect of fluvoxamine on panic disorder
18. Mixed anxiety and depression
19. Medically unexplained symptoms in primary care
20. Somatisation: A spectrum of severity
21. Sertraline for social phobia: A double-blind, placebo-controlled crossover study
22. Symptoms in the community: Prevalence, classification and psychiatric comorbidity
23. A multicentre double blind comparative trial of fluvoxamine vs lorazepam in mixed anxiety and depression treated in general practice
24. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder
25. Efficacy studies of paroxetine in panic disorder
26. Quality of life and posttraumatic stress disorder: A pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine
27. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder
28. Serotonin but not norepinephrine induced calcium mobilisation of platelets is enhanced in affective disorders
29. The efficacy of fluoxetine as an antidepressant in the short and long term
30. A double blind comparison of zimelidine and amitriptyline in endogenous depression
31. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder
32. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study
33. The platelet intracellular calcium response to serotonin and thrombin in patients with panic disorder
34. Clinical effects of fluvoxamine on panic symptomatology
35. Beyond signs and symptoms: The case against a mixed anxiety and depression category
36. Paroxetine efficacy in the treatment of generalized anxiety disorder
37. Sertraline in the treatment of rape victims with posttraumatic stress disorder
38. Generalised anxiety and mixed anxiety depression: Association with disability and health care utilisation
39. Fluvoxamine, placebo, and cognitive behavior therapy used alone and in combination in the treatment of panic disorder and agoraphobia
40. The treatment of panic disorder with paroxetine
41. Mixed depression and anxiety: Role of serotonin 1A
42. Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation
43. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
44. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study
45. Fluoxetine, placebo and tricyclic antidepressants in major depression with and without anxious features
46. Fluoxetine in posttraumatic stress disorder
47. A double-blind placebo controlled study with fluvoxamine
48. The effect of citalopram in panic disorder
49. The DSM-IV field trial for mixed anxiety-depression